An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Median progression free survival according to tumor assessments
2.5 years
No
Clinical Trials
Study Director
Hoffmann-La Roche
India: Drug Controller General
ML25477
NCT01260194
June 2011
August 2018
Name | Location |
---|